Dynavax Technologies Corporation (DVAX)

NASDAQ
12.860
-0.290(-2.21%)
After Hours
12.880
+0.020(+0.156%)
- Real-time Data
  • Volume:
    2,368,283
  • Bid/Ask:
    12.760/12.880
  • Day's Range:
    12.740 - 13.550

DVAX Overview

Prev. Close
13.15
Day's Range
12.74-13.55
Revenue
263.92M
Open
12.81
52 wk Range
5.27-21.39
EPS
-0.34
Volume
2,368,283
Market Cap
1.54B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,274,227
P/E Ratio
-
Beta
1.35
1-Year Change
146.36%
Shares Outstanding
119,952,132
Next Earnings Date
09 Mar 2022
What is your sentiment on Dynavax Technologies Corporation?
or
Market is currently closed. Voting is open during market hours.

Dynavax Technologies Corporation Company Profile

Employees
245

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), pertussis, and universal influenza.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellNeutral
  • Sold at $18,60 with nice $10 gain Will buy back if there is the anticipated market correction later this year.Believe stock could easily reach $25 plus when looking at its Financials and Drug research/production.
    0
    • 30 once covid 19 vaccine success
      0
      • Hope so; still looking good after buying at $7,25
        0
    • Big year for DVAX, numerous contracts signed, expecting to hit past the 20s soon
      0
      • Big year for DVAX, numerous contracts signed
        0
        • Got out at $9.7 with 100% profit. May buy again if price sinks further but a volatile ride.
          0
          • now this will be on the rise...earnings coming next week and will rocket!
            0
        • whoever thinks this will rocket hit like button!
          1
          • There Hep B Vaccine will produce revenue if they don't find a vaccine for covid 19
            0
            • As of today India anounced the vaccine for COVID-19,
              0
            • Yes but India's process of getting a vaccine into the market is different there is less red tape and less regulations to follow.
              0
            • Yes but their revenue recent results were very poor !
              0
          • bright future!
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.